BioAtla, Inc.

BIOATLA APPOINTS ERIC SIEVERS, M.D., AS CHIEF MEDICAL OFFICER Experienced leader of oncology clinical trial approvals to head BioAtla’s clinical development programs SAN DIEGO, CA June 28, 2019 - BioAtla, LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced the appointment of Eric L. Sievers, M.D., as chief medical officer. Dr. Sievers, an experienced biotechnology drug developer in on...Continue reading

BIOATLA AND BEIGENE FORM WORLDWIDE COLLABORATION TO DEVELOP AND COMMERCIALIZE NOVEL CONDITIONALLY ACTIVE BIOLOGIC CTLA-4 THERAPY Plan to pursue development as a monotherapy and in combination with BeiGene’s investigational anti-PD-1 antibody, tislelizumab San Diego, CA; Beijing, China and Cambridge, MA, April 8, 2019 BioAtla , LLC, a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics, and Be...Continue reading

BIOATLA PRESENTS CAB-CTLA-4 AND CAB-EpCAM-ADC DATA AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING Oral presentation highlights CAB-CTLA-4 pre-clinical data demonstrating expected efficacy and reduced immune side effects and toxicities as monotherapy or in combination with PD-1 inhibitors Poster presentation of CAB-EpCAM-ADC demonstrating anti-tumor efficacy in vivo...Continue reading

Congratulations Dr. Allison! https://www.mdanderson.org/newsroom/nobel-prize.html